SWStefan De Wachter

Stefan De Wachter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefan De Wachter has a total of 263 co-authors. Here are the top co-authors by number of shared publications:

  • Gunter De Win

    Department of Urology Antwerp University Hospital Edegem Belgium

    12 shared publications
  • Donald Vaganée

    Department of Urology Antwerp University Hospital Edegem Belgium

    9 shared publications
  • Alexandra Vermandel

    Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

    7 shared publications
  • Sigrid Van de Borne

    Department of Urology, Antwerp University Hospital, Edegem, Belgium; Department of Urology, Antwerp Surgical Training, Anatomy and Research Centre, Faculty of Medicine and Health Sciences, Anatomy, University of Antwerp, Antwerp, Belgium

    6 shared publications
  • Donald Vaganée

    Department of Urology, Antwerp University Hospital, Edegem, Belgium; Department of Urology, Antwerp Surgical Training, Anatomy and Research Centre, Faculty of Medicine and Health Sciences, Anatomy, University of Antwerp, Antwerp, Belgium

    5 shared publications
  • Jean Jacques Wyndaele

    Faculty GGW University of Antwerp Brasschaat Belgium

    5 shared publications

Latest Publications

  • Longitudinal genital growth curves in adolescents and Doppler‐based varicocele risk stratification

    by De Win Gunter, Klein Judith, Janssen Judith, De Baets Karen, Brits Tim, De Wachter Stefan, Van Dongen Stefan, Vaganée Donald

    Objectives: To construct longitudinal ultrasound‐based growth curves for genital development and to assess the prognostic value of varicocele grade and Doppler features. Varicoceles affect ~20% of adolescent boys and can be associated with impaired fertility. Evidence‐based criteria for intervention are lacking due to limited longitudinal data. Subjects, Patients and Methods: We conducted a prospective longitudinal cohort study (2015–2021) of 570 boys aged 10.5–18 years (407 controls, 163 with left‐sided varicocele; 1352 assessments). The boys underwent Tanner pubic hair staging (TSP), measurement of stretched penile length (SPL), and a scrotal ultrasound. The volumes of the left and right testes and total testicular volume (TTV) were calculated according to the Lambert formula. In varicocele, venous diameter (VD), spontaneous reflux (SR), peak retrograde flow (PRF), and clinical grade were measured. Growth trajectories were analysed using mixed‐effects models. Results: Severe subgroups (VD ≥3 mm, SR >20 cm/s, or Grade 3) had attenuated growth slopes and lower TTV at TSP 5 vs controls. Combined risk profiles (e.g., Grade 3 + VD ≥3 mm; SR >20 cm/s + Grade 3) showed the poorest outcomes, with final TTV consistently 38.4 cm/s alone was not predictive. The SPL differences were minimal. Some subgroups entered puberty earlier but progressed more slowly. Limitations include absence of semen and hormonal data, exclusion of atypical developmental disorders, and limited ethnic diversity. Conclusions: Most adolescents with a varicocele develop normally. Only those with combined high‐risk Doppler and clinical features show impaired testicular growth. Doppler adds prognostic value beyond grade and supports a stratified surveillance strategy, potentially reducing overtreatment.

  • Open Access

    Genetic Heterogeneity in Renal Cell Carcinoma: A Case of Concurrent Clear Cell and Papillary Renal Carcinomas

    by Annelies Kerckhofs, Stéphanie Dautricourt, Léon van Kempen, Stefan De Wachter, Ali Ramadhan

    Background/Objectives: Recent advancements in genetic research have significantly enhanced the understanding of renal cell carcinoma (RCC), now recognized as a heterogeneous group with distinct genetic features. This case report is aimed at illustrating its genetic diversity and implications for diagnosis and treatment. Methods: A middle‐aged man presented with an incidental finding of RCC in the right kidney on computer tomography (CT) performed for a persistent cough. Comprehensive radiological and blood tests were conducted, followed by a total right nephrectomy. Histological examination showed a concurrent appearance of two manifestly different tumors in the kidney. Molecular analyses, including SNP array and next‐generation sequencing (NGS), were conducted to identify genetic mutations and assess clonality. Results: The nephrectomy identified two distinct tumors: a clear cell RCC (ISUP/WHO grade 3, pT1b) and a papillary RCC (ISUP/WHO grade 2, pT1a). Molecular analysis confirmed VHL , TP53 , and SETD2 mutations in the clear cell RCC, whereas no mutations were detected in the papillary RCC. The SNP array revealed significant chromosomal differences, suggesting the tumors were not clonally related. Follow‐up imaging detected an adrenal metastasis from the clear cell RCC. The metastasis showed a VHL and SETD2 mutation, which undoubtedly proved to be derived from the clear cell RCC. Conclusions: This case underscores the genetic heterogeneity of RCC and the importance of molecular profiling in guiding diagnosis and treatment. The distinct genetic profiles of the two tumors suggest they are not clonally related, highlighting the complexity of RCC and the need for individualized therapeutic approaches.

  • Open Access

    Home uroflowmetry – Looking beyond the single flow test

    by Stefan De Wachter, Eduard Van Beeck Morales, Gunter De Win


  • Do disposable diapers reduce urination elimination signals in non-toilet-trained children?

    by Lola Bladt, Tinne Van Aggelpoel, Gunter De Win, Stefan De Wachter, Lukas Van Campenhout, Alexandra Vermandel

    Elimination signals play a key role in facilitating toilet training. This pilot study assessed whether disposable diapers affect urination elimination signals in typically developing children aged 18 to 36 months who are not yet toilet trained. A prospective observational pilot study with a within-subject design was conducted under two conditions, presented in a fixed order: first diaper-free, then with a diaper. Three trained researchers conducted real-time and video-recorded observations, using a urination elimination signals checklist. Of the 28 children enrolled, complete data was available for 23 (10 boys, 13 girls, mean age 24 months, SD 3.1 months, range 19–30 months). Descriptive statistics and logistic regression were used to assess the effect of wearing a diaper on the display of urination elimination signals. More children showed elimination signals when diaper-free. Significant differences were found in the proportion of children who verbally expressed the need to void (43% vs. 13%, p = 0.029), sought caregiver contact (52% vs. 13%, p = 0.008), showed lower limb movement (87% vs. 35%, p = 0.0009), ceased activity (87% vs. 35%, p = 0.0009), and touched or looked at the genital area both before (74% vs. 30%, p = 0.004) and during urination (78% vs. 13%, p = 0.00007). When grouped by urination phase, significant differences were found before (p = 0.045), during (p = 0.0009), and after urination (p = 0.0008). Conclusion: This is the first prospective study to show that disposable diaper use is associated with a reduced display of urination elimination signals. Further research is needed to explore how this reduction might impact toilet training initiation timing and, in turn, continence outcomes. What is known: • Elimination signals are cues exhibited by children before, during, or after urination and play a key role in facilitating toilet training. • A trend toward later toilet training initiation has been observed in Western countries in parallel with the widespread use of highly absorbent disposable diapers. What is new: • This is the first prospective study to assess the effect of disposable diapers on the display of urination elimination signals in non-toilet-trained children. • In our study, children were more likely to show elimination signals in the diaper-free condition compared to the disposable diaper condition.

  • Donor site morbidity and impact on oral health following buccal mucosal graft harvesting for urethroplasty: a prospective study

    by Devang Desai, Sachin Joshi, Kapilan Ravichandran, Hannah Flynn, Stefan De Wachter, Gunter De Win

    Purpose To evaluate patient-reported oral health and pain and buccal donor site complications in adults who underwent BMG harvesting utilizing two validated questionnaires. Materials and methods An ethics-approved prospective observational study was conducted among a cohort of 40 adults who had a BMG urethroplasty between June 2020 and October 2021. All cases were performed by one fellowship-trained genitourinary reconstructive surgeon. Oral health was appraised before and after BMG harvesting via the validated Oral Impacts of Daily Performance (OIDP) questionnaire. Post-operative pain at the BMG donor site was assessed by administering the Visual Analogue Scale for pain (VAS) both pre-and post-operatively. Statistical analysis was undertaken to identify risk factors for increased post-operative pain and decreased oral health. Results The cohort included sub-meatal, penile, bulbar, and pan-urethral strictures. Most cases (36/40) were a primary urethroplasty, but 4 cases were a re-do urethroplasty. Only 5 participants (12.5%) experienced complication(s) at the donor site such as bleeding (2/40, 5%), infection (1/40, 2.5%), hyper granulation tissue (1/40, 2.5%), and long-term difficulty with mouth opening (3/40, 7.5%). Most participants (32/40, 80%) had at least one daily oral performance affected by BMG harvesting. Eating, speaking, and cleaning teeth were the most impacted domains. However, there was no statistically significant decrease in oral health at either 3- or 6 months post-BMG harvesting (p < 0.05). Almost all participants (38/40, 95%) reported no pain at the donor site before BMG harvesting. Pain at the donor site peaked at 1 week post-operatively (28/40, 70%), but the majority were pain-free by 3 months post-BMG harvesting (35/40, 87.5%). Conclusion BMG harvesting is an effective means of procuring a suitable graft for urethroplasty. Whilst pain at the donor site is experienced in the immediate post-operative period, long-term pain is a rare complication. Overall oral health is not detrimentally impacted by BMG harvesting.


  • Measuring the impact of disposable diapers on urination elimination signals in non-toilet-trained children

    by Lola Bladt, Tinne Van Aggelpoel, Gunter De Win, Stefan De Wachter, Lukas Van Campenhout, Alexandra Vermandel


  • Reply to Letter to the Editor on “The Added Value of Home-Uroflowmetry: Analyzing an Individuals’ VV-Qmax Curve and Inflection Point”

    by Gunter De Win, Matthew Peters, Jasper Pauwels, Eduard Van Beeck Morales, Sascha Vereeck, Alexandra Vermandel, Stefan Van Dongen, Stefan De Wachter

  • An Overview of Novel Devices for Tibial Nerve Stimulation in Urinary Incontinence

    by Charlotte Defour, Jakob De Wachter, Stefan De Wachter


  • Open Access

    The Added Value of Home-Uroflowmetry: Analyzing an Individuals’ VV-Qmax Curve and Inflection Point

    by Gunter De Win, Matthew Peters, Jasper Pauwels, Eduard Van Beeck Morales, Sascha Vereeck, Alexandra Vermandel, Stefan Van Dongen, Stefan De Wachter


  • Open Access

    Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence

    by John P. F. A. Heesakkers, Philip Toozs-Hobson, Suzette E. Sutherland, Alex Digesu, Cindy L. Amundsen, Rebecca J. McCrery, Stefan De Wachter, Emily R. Kean, Frank Martens, Kevin Benson, et al.

    The BlueWind Medical Device, Revi®, is a novel implantable tibial neuromodulation system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence (i.e., overactive bladder wet). The Revi System is the first FDA-cleared implantable neuromodulation device which can be used without prior failure with more conservative treatment options. Two-year follow-up results of the OASIS Study are presented. The Revi System was implanted in 151 female participants. The primary efficacy and safety endpoints were assessed at 6- and 12-months, after which participants either consented to extend follow-up for long-term assessment of treatment durability and safety, or they chose to exit the study. Ninety-seven participants completed the 24-month assessment, and of these, 79% were therapy responders (≥ 50% reduction in urgency urinary incontinence episodes (UUIE), demonstrated on a 3-day voiding diary). Importantly, therapeutic response was durable, with comparable effectiveness at 6-, 12-, and 24-months (response rates of 78%, 82%, and 79%, respectively). Participants that completed both the 6- and 24-month assessment had similar demographics and treatment results at the 6-month visit, indicating that these results at 24-months are representative of the overall study population.In addition, high satisfaction and patient impression of improvement were reported, with 97% (88/91) of the participants satisfied with the therapy and 80% (78/97) feeling "much better" or "very much better". There were no serious adverse events related to the device or the procedure through 24 months. Two-year results demonstrate durable efficacy, high patient satisfaction, and a very favorable safety profile.